Noel R. Dasgupta

Research Field

Cardiac Amyloidosis

10.1016/j.cardfail.2024.10.322

Cite

Citations (0)

Amyloid (2019)

Oscar W. Cummings Noel R. Dasgupta Merrill D. Benson

While originally described as renal amyloidosis manifest by nephrotic syndrome followed by azotaemia, increasing numbers of patients have been found to have hepatic ALECT2 with or without signs of ...

10.1080/13506129.2019.1584099

Cite

Citations (0)

PRO78 Extent and Consequences of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy: A Targeted Literature Review of the Patient Journey

Value in Health (2020)

Mark H. Rozenbaum Samuel Large Rahul Bhambri Michael Stewart Beverley Jones

10.1016/j.jval.2020.08.1814

Cite

Citations (0)

Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis

Blood (2024)

Hassan Kawtharany Muayad Azzam Jamil Nazzal Vishal Kukreti Matthew D. Seftel

Cardiac Amyloidosis

10.1182/blood-2024-210831

Cite

Citations (0)

Long-term Treatment with Inotersen for Amyloid Transthyretin Amyloidosis Cardiomyopathy

Journal of Cardiac Failure (2018)

Noel R. Dasgupta Merrill D. Benson

Amyloid (mycology)

Cardiac Amyloidosis

10.1016/j.cardfail.2018.07.263

Cite

Citations (1)

An aggressive form of transthyretin amyloidosis

Amyloid (2017)

Noel R. Dasgupta Annabel K. Wang Joyce Hardwick Merrill D. Benson

In 1990, Ueno et al. identified a new transthyretin (TTR) mutation in a 45-year-old Japanese man with peripheral neuropathy of six-years duration [1]. This mutation, Ser50Arg, was the result of a s...

10.1080/13506129.2017.1284057

Cite

Citations (1)

Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Blood (2024)

Jamil Nazzal Muayad Azzam Hassan Kawtharany Vishal Kukreti Matthew D. Seftel

Immunofixation

AL amyloidosis

10.1182/blood-2024-211780

Cite

Citations (0)

Familial wild-type transthyretin cardiomyopathy

Amyloid (2017)

Merrill D. Benson John L. Berk Lawreen H. Connors Noel R. Dasgupta

Transthyretin (TTR) amyloidosis was originally described as an autosomal dominant inherited systemic disease with peripheral neuropathy being the paramount feature. It was obvious from the first de...

Restrictive cardiomyopathy

10.1080/13506129.2017.1281118

Cite

Citations (0)

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review

Cardiology and Therapy (2021)

Mark H. Rozenbaum Samuel Large Rahul Bhambri Michelle Stewart Jo Whelan

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal and under-recognized disease. This targeted literature review assessed the extent and consequences of diagnostic delay and misdiagnosis in ATTR-CM. The Embase database was searched together with proceedings of eight cardiology conferences to identify publications or abstracts on ATTR-CM. Outcomes of interest were time from symptom onset to diagnosis, rates of delayed diagnosis and misdiagnosis, and costs, healthcare resource use or clinical outcomes whilst undiagnosed/misdiagnosed. Twenty-three articles were included. Weighted means of reported mean and median diagnostic delays were 6.1 and 3.4 years for wild-type (ATTRwt-CM) and 5.7 and 2.6 years for hereditary (ATTRv-CM). Misdiagnosis occurred in 34–57% of patients when reported. Evaluation and misdiagnosis by multiple healthcare providers before receiving an ATTR-CM diagnosis was common, and there was evidence that patients undergo unnecessary or inappropriate evaluations or treatments while misdiagnosed. Diagnostic "red flags" were reported to be underused. Data on the consequences of delay for patients and health systems were sparse, but given the progressive nature of ATTR-CM, delay is likely to have adverse consequences. ATTR-CM patients commonly experience diagnostic delay and misdiagnosis. Efforts are required to provide timely diagnosis so that patients can benefit from earlier access to new disease-modifying therapies.

Amyloid (mycology)

10.1007/s40119-021-00219-5

Cite

Citations (69)

Amyloid Cardiomyopathy ∗

Journal of the American College of Cardiology (2016)

Merrill D. Benson Noel R. Dasgupta

10.1016/j.jacc.2016.05.009

Cite

Citations (15)